Substance use in pregnancy: No. 256, April 2011

International Journal of Gynecology and Obstetrics

Volumn 114, Issue 2, 2011, Pages 190-202

[No Author Info available]

Author keywords

Neonatal abstinence syndrome; Pregnancy; Substance use; substance related disorders

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE DERIVATIVE; ANALGESIC AGENT; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; BUTORPHANOL; CANNABIS; COCAINE; CODEINE; DIAMORPHINE; METHADONE; MORPHINE; NALBUPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; NICOTINE; NICOTINE GUM; NICOTINE PATCH; OPIATE; OPIATE AGONIST; OXYCODONE; PENTAZOCINE; PHENOBARBITAL; PSYCHEDELIC AGENT; SOLVENT; VARENICLINE;

ARTICLE; AWARENESS; BREAST FEEDING; CANNABIS ADDICTION; CHRONIC PAIN; CLINICAL ASSESSMENT TOOL; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COCAINE DEPENDENCE; COCHRANE LIBRARY; COGNITIVE THERAPY; DISEASE SEVERITY; DROWSINESS; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; HEALTH CARE PERSONNEL; HEROIN DEPENDENCE; HUMAN; INHALANT ABUSE; KNOWLEDGE; LACTATION; MASS SCREENING; MATERNAL CARE; MATERNAL MORBIDITY; MATERNAL MORTALITY; MEDICAL TECHNOLOGY; MEDLINE; NEWBORN MORBIDITY; NEWBORN MORTALITY; NICOTINE REPLACEMENT THERAPY; OPIATE ADDICTION; OPIOID OVERDOSE; OUTCOME ASSESSMENT; PATIENT COUNSELING; POSTPARTUM PAIN; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL CARE; PRIORITY JOURNAL; PSYCHOTHERAPY; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SLURRED SPEECH; SMOKING CESSATION PROGRAM; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; TOBACCO; TOBACCO DEPENDENCE; WEB BROWSER; WITHDRAWAL SYNDROME;

EID: 79960198282     PISSN: 00207292     EISSN: 18793479     Source Type: Journal    
DOI: 10.1016/j.ijgo.2011.06.001     Document Type: Article

References (161)

1. Health Canada. Canadian perinatal health report. Ottawa: Minister of Public Works and Government Services Canada; 2003
2. Statistics Canada. Canadian community health survey (CCHS), Cycle 1.1. Ottawa: Statistics Canada; 2002. Available at:www.statcan.ca/english/concepts/ health/index.htm [Accessed December 22, 2010]
3. Substance Abuse and Mental Health Services Administration. Results from the 2007 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-34, DHHS Publication No. SMA 08-4343); 2008. [Rockville, MD]
4. Giles W, Patterson T, Sanders F, Batey R, Thomas D, Collins J. Outpatient methadone programme for pregnant heroin using women. Aust N Z J Obstet Gynecol 1989;29(3 Pt 1):225-9 (Pubitemid 19217015)
5. Lutiger B, Graham K, Einarson TR, Koren G. Relationship between gestational cocaine use and pregnancy outcome: a meta-analysis. Teratology 1991;44:405-11
6. DiFranza JR, Lew RA. Effect of maternal cigarette smoking on pregnancy complications and sudden infant death syndrome. J Fam Pract 1995;40:385-94
7. Little BB, Wilson G, Jackson G. Is there a cocaine syndrome? Dysmorphic and anthropometric assessment of infants exposed to cocaine. Teratology 1996;54:145-9 (Pubitemid 27042476)
8. Makarechian N, Agro K, Devlin J, Trepanier E, Koren G, Einarson TR. Association between moderate alcohol consumption during pregnancy and spontaneous abortion, stillbirth and premature birth: a meta-analysis. Can J Clin Pharmacol 1998;5:169-76 (Pubitemid 28463955)
9. Kuhn L, Kline J, Ng S, Levin B, Susser M. Cocaine use during pregnancy and intrauterine growth retardation: new insights based on maternal hair tests. Am J Epidemiol 2000;152(2):112-9 (Pubitemid 30463658)
10. Ernst M, Moolchan ET, Robinson ML. Behavioral and neural consequences of prenatal exposure to nicotine. J Am Acad Child Adolesc Psychiatry 2001;40(6): 630-41 (Pubitemid 32473376)
11. US Centers for Disease Control and Prevention. The health consequences of smoking: a report of the Surgeon General. Office on Smoking and Health; 2004 [cited 2009 April 4]. Available at:http://www.cdc.gov/tobacco/data-statistics/ sgr/sgr-2004/index.htm [Accessed December 22, 2010]
12. Fajemirokun-Odudeyi O, Sinha C, Tutty S, Pairaudeau P, Armstrong D, Phillips T, et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol 2006;126:170-5
13. Araojo R, McCune S, Feibus K. Substance abuse in pregnant women: making improved detection a good clinical outcome. Clin Pharmacol Ther 2008;83: 520-2 (Pubitemid 351417074)
14. Binder T, Vavrinkova B. Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro Endocrinol Lett 2008;29:80-6
15. Delpisheh A, Brabin L, Drummond S, Brabin BJ. Prenatal smoking exposure and asymmetric fetal growth restriction. Ann Hum Biol 2008;35:573-83
16. Floyd RL, Jack BW, Cefalo R, Atrash H, Mahoney J, Herron A, et al. The clinical content of preconception care: alcohol, tobacco, and illicit drug exposures. Am J Obstet Gynecol 2008;199(6 Suppl. 2):S333-9
17. Vucinovic M, Roje D, Vucinovic Z, Capkun V, Bucat M, Banovic I. Maternal and neonatal effects of substance abuse during pregnancy: our ten year experience. Yonsei Med J 2008;49:705-13
18. Edelin KC, Gurganious L, Golar K, Dellerich D, Kyei-Aboagye K, Hamid MA. Methadone maintenance in pregnancy: consequences to care and outcome. Obstet Gynecol 1988;71:399-404
19. Chang G, Carroll KM, Behr HM, Kosten TR. Improving treatment outcome in pregnant opiate-dependent women. J Subst Abuse Treat 1992;9:327-30 (Pubitemid 23052629)
20. Rehm J, Baliunas D, Brochu S, Fischer B, Gnam W, Patra J, et al. The costs of substance abuse in Canada 2002: highlights. Canadian Centre on Substance Abuse; April 2006. Available at:http://www.ccsa.ca/Eng/Priorities/ Research/CostStudy/Pages/default.aspx. [Accessed December 27, 2010]
21. Chiu TT, Vaughn AJ, Carzoli RP. Hospital costs for cocaine-exposed infants. J Fla Med Assoc 1990;77:897-900
22. Adams EK, Miller VP, Ernst C, Nishimura BK, Melvin C, Merritt R. Neonatal health care costs related to smoking during pregnancy. Health Econ 2002;11:193-206 (Pubitemid 34284845)
23. Hutson J. A prenatal perspective on the cost of substance abuse in Canada. JFAS Int 2006;4(e9):1-4
24. Lefebvre LG, Ordean A, Midmer D, Kahan M, Tolomiczenko G. Physicians' knowledge of alcohol, tobacco and folic acid in pregnancy. J Subst Abuse 2007;28: 3-9
25. Leversha AM, Marks RE. Alcohol and pregnancy: doctors' attitudes, knowledge and clinical practice. N Z Med J 1995;108:428-30
26. Gehshan S. Missed opportunities for intervening in the lives of pregnant women addicted to alcohol or other drugs. J Am Med Womens Assoc 1995;50:160-3
27. Public Health Agency of Canada. Knowledge and attitudes of health professionals about fetal alcohol syndrome: results of a national survey. Available at:http://www.phac-aspc.gc.ca/publicat/fasd-surv-etcafenquete/index. html. [Accessed November 23, 2010]
28. Nevin AC, Christopher P, Nulman I, Koren G, Einarson A. A survey of physicians knowledge regarding awareness of maternal alcohol use and the diagnosis of FAS. BMC Fam Pract 2002;3:2-6
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., Text Revision (DSM-IV-TR). Arlington: American Psychiatric Publishing Inc; 2000
30. Brands B, Kahan M, Selby P, Wilson L, editors. Management of alcohol, tobacco and other drug problems: a physician's manual. Toronto: Centre for Addiction and Mental Health; 2000
31. Office of Maternal and Child Health. Substance abuse during pregnancy: guidelines for screening. Washington State Department of Health; 2008. Available at:http://www.doh.wa.gov/cfh/mch/documents/ScreenGuideline.pdf. [Accessed April 2, 2009]
32. Hinderliter SA, Zelenak JP. A simple method to identify alcohol and other drug use in pregnant adults in a prenatal care setting. J Perinatol 1993;13:93-102
33. Chang G, Wilkins-Haug L, Berman S, Goetz MA, Behr H, Hiley A. Alcohol use and pregnancy: improving identification. Obstet Gynecol 1998;91:892-8 (Pubitemid 28246919)
34. Chang G, Wilins-Halig L, Berman S, Goetz MA. The TWEAK: Application in a prenatal setting. J Stud Alcohol 1999;60:306-9 (Pubitemid 29214830)
35. Carroll JC, Reid AJ, Biringer A, Midmer D, Glazier RH, Wilson L, et al. Effectiveness of the Antenatal Psychosocial Health Assessment (ALPHA) form in detecting psychosocial concerns: a randomized controlled trial. CMAJ 2005;173:253-9 (Pubitemid 41097738)
36. Reid AJ, Biringer A, Carroll JD, Midmer D, Wilson LM, Chalmers B, et al. Using the ALPHA form in practice to assess antenatal psychosocial health. Antenatal Psychosocial health assessment. CMAJ 1998;159:677-84 (Pubitemid 28474627)
37. Office of Maternal and Child Health. Guidelines for Testing and Reporting Drug Exposed Newborns. Washington State Department of Health; 2008. Available at: http://www.doh.wa.gov/cfh/mch/documents/HospTestDrug.pdf. [Accessed April 2, 2009]
38. Ostrea EM, Knapp DK, Tannenbaum L, Ostrea AR, Romero A, Salari V, et al. Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. J Pediatr 2001;138:344-8 (Pubitemid 32207135)
39. Gourlay D, Heit HA, Caplan YH. Urine drug testing in primary care. USA: PharmaCom Group Inc.; 2002
40. Callahan CM, Grant TM, Phipps P, Clark G, Novack AH, Streissguth AP, et al. Measurement of gestational cocaine exposure: sensitivity of infants' hair, meconium, and urine. J Pediatr 1992;120:763-8
41. Vinner E, Vignau J, Thibault D, Codaccioni X, Brassart C, Humbert L, et al. Neonatal hair analysis contribution to establishing a gestational drug exposure profile and predicting a withdrawal syndrome. Ther Drug Monit 2003;25:421-32 (Pubitemid 36927972)
42. Christmas JT, Knisely JS, Dawson KS, Dinsmoor MJ, Weber SE, Schnoll SH. Comparison of questionnaire screening and urine toxicology for detection of pregnancy complicated by substance use. Obstet Gynecol 1992;80:750-4
43. Kwong TC, Shearer D. Detection of drug use during pregnancy. Obstet Gynecol Clin North Am 1998;25:43-64 (Pubitemid 28141700)
44. Gehringer K. Informed consent: hospitals must obtain informed consent prior to drug testing pregnant patients. J Law Med Ethics 2003;31:455-7 (Pubitemid 39307079)
45. Mikhail BI. Perceived impediments to prenatal care among low-income women. West J Nurs Res 1999;21:335-50 [discussion 351-5]
46. Milligan R, Wingrove BK, Richards L, Rodan M, Monroe-Lord L, Jackson V, et al. Perceptions about prenatal care: views of urban vulnerable groups. BMC Public Health 2002;2:25
47. Currie JC. Best practices treatment and rehabilitation for women with substance use problems. Ottawa: Minister of Public Works and Government Services Canada; 2001. Available at:http://www.cds-sca.com. [Accessed November 23,2010]
48. Roberts G, Nanson J. Best practices: fetal alcohol syndrome/fetal alcohol effects and the effects of other substance use during pregnancy. Ottawa: Minister of Public Works and Government Services Canada; 2001
49. Ellwood DA, Sutherland P, Kent C, O'Connor M. Maternal narcotic addiction: pregnancy outcome in patients managed by a specialized drug- dependency antenatal clinic. Aust N Z J Obstet Gynecol 1987;27:92-8 (Pubitemid 17131895)
50. Kandall SR, Albin S, Lowinson J, Berle B, Eidelman AI, Gartner LM. The narcoticdependent mother: fetal and neonatal consequences. Early Hum Dev 1977;1: 159-69
51. Lee MI, Stryker JC, Sokol RJ. Perinatal care for narcotic-dependent gravidas. Perinatol Neonatol 1985;9(6):35-40
52. Burkett G, Gomez-Marin O, Yashin SY, Martinez M. Prenatal care in cocaineexposed pregnancies. Obstet Gynecol 1998;92:193-200
53. Jansson LM, Svikis D, Lee J, Paluzzi P, Rutiglioano P, Hackerman F. Pregnancy and Addiction. A comprehensive care model. J Subst Abuse Treat 1996;13:321-9
54. Sweeney PJ, Schwartz RM, Mattis NG, Vohr B. The effect of integrating substance abuse treatment with prenatal care on birth outcome. J Perinatol 2000;20: 219-24
55. Reece EA, Leguizamon G, Silva J, Whiteman V, Smith D. Intensive interventional maternity care reduces infant morbidity and hospital costs. J Matern Fetal Neonatal Med 2002;11:204-10 (Pubitemid 34836935)
56. Suffet F, Brotman R. A comprehensive care program for pregnant addicts: obstetrical, neonatal, and child development outcomes. Int J Addict 1984;19: 199-219 (Pubitemid 14116148)
57. McLaughlin FJ, Altemeier WA, Christensen MJ, Sherrod KB, Dietrich MS, Stern DT. Randomized trial of comprehensive prenatal care for low- income women: effect on infant birth weight. Pediatrics 1992;89:128-32
58. Scholl TO, Hediger ML, Belsky DH. Prenatal care and maternal health during adolescent pregnancy: a reviewand meta-analysis. JAdolesc Health 1994;15:444-56 (Pubitemid 24300261)
59. Wong T, Lee SS. Hepatitis C: a review for primary care physicians. CMAJ 2006;174:649-59 (Pubitemid 43341876)
60. Robinson JL. Vertical transmission of the hepatitis C virus: current knowledge and issues. Paediatr Child Health 2008;13:529-36
61. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. The NSDUH report: sexually transmitted diseases and substance use; 2007 [Rockville, MD]
62. Fichtner R, Carson D, Brackbill R. Behavioural risks for HIV/STD and birth outcomes among pregnant women who abuse substances: evidence from intensive outreach-Atlanta, Georgia. Int Conf AIDS 1996;11:362 [abstract]
63. Bolnick JM, Rayborn JM, Rayborn WF. Substance use disorders in women: special considerations during pregnancy. Obstet Gynecol Clin North Am 2003;30: 545-58 (Pubitemid 37420311)
64. Schempf AH, Strobino DM. Illicit drug use and adverse birth outcomes: is it drugs or context? J Urban Health 2008;85:858-73
65. Bailey BA, Daugherty RA. Intimate partner violence during pregnancy: incidence and associated health behaviors in a rural population. Matern Child Health J 2007;11:495-503 (Pubitemid 47097490)
66. Liston R, Sawchuck D. SOGC Fetal Health Surveillance Consensus Committee. Fetal health surveillance: antepartum and intrapartum consensus guideline. SOGC Clinical Practice Guideline No. 197, September 2007. J Obstet Gynecol Can 2007;29(Suppl. 4):S1-S56
67. Chang G, Goetz MA, Wilkins-Haug L, Berman S. A brief intervention for prenatal alcohol use: an in-depth look. J Subst Abuse Treat 2000;18:365-9 (Pubitemid 30254360)
68. The Project CHOICES Intervention Research Group. Reducing the risk of alcoholexposed pregnancies: a study of a motivational intervention in community settings. Pediatrics 2003;111:1131-5
69. Nordstrom BR, Levin FR. Treatment of cannabis disorders: a review of the literature. Am J Addict 2007;16:331-42 (Pubitemid 47450754)
70. Dutra L, Stathopolou G, Basden SL, Leyro TM, Powers MB, Otto MW. A metaanalytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008;165:179-87 (Pubitemid 351704516)
71. Carroll KM, Chang G, Behr H, Clinton B, Kosten TR. Improving treatment outcome in pregnant, methadone-maintained women: results from a randomized clinical trial. Am J Addict 1995;4:56-9
72. Davis MM, Brown BS, Glendinning ST. Neonatal effects of heroin addiction and methadone-treated pregnancies. Preliminary report on 70 live births. Proc Natl Conf Methadone Treat 1973;2:1153-64
73. Harper RG, Solish GI, Sang E, Purow H. The effect of a methadone treatment program upon pregnant addicts and their infants. Proc Natl Conf Methadone Treat 1973;2:1133-7
74. H. Johnson. Measuring violence against women: statistical trends 2006. Statistics Canada catalogue no. 85-570-XWE, Ottawa
75. Messer K, Clarke KA, Martin SL. Characteristics associated with pregnant women's utilization of substance abuse treatment services. Am J Drug Alcohol Abuse 1996;22:403-22 (Pubitemid 26256210)
76. Martin SL, Beaumont JL, Kuper LL. Substance use before and during pregnancy: links to intimate partner violence. Am J Drug Alcohol Abuse 2003;29:599-617 (Pubitemid 37093369)
77. Tuten M, Jones HE. A partner's drug-using status impacts women's drug treatment outcome. Drug Alcohol Depend 2003;70:327-30 (Pubitemid 36577344)
78. Kissin WB, Svikis DS, Morgan GD, Haug NA. Characterizing pregnant drug-dependent women in treatment and their children. J Subst Abuse Treat 2001;21:27-34 (Pubitemid 32757238)
79. Kissin WB, Svikis DS, Moylan P, Haug NA, Stitzer ML. Identifying pregnant women at risk for early attrition from substance abuse treatment. J Subst Abuse Treat 2004;27:31-8 (Pubitemid 38829776)
80. Tough SC, Siever JE, Johnston DW. Retaining women in a prenatal care randomized controlled trial in Canada: implications for program planning. BMC Public Health 2007;7:148
81. Ontario Ministry of Children and Youth Services. Reporting child abuse and neglect: it's your duty. Queen's Printer for Ontario; 2005. Available at:http://www.children.gov.on.ca/htdocs/English/topics/childrensaid/ reportingabuse/abuseandneglect/abuseandneglect.aspx. [Accessed December 22, 2010]
82. Rore C, Brace V, Danielian P, Williams D. Smoking cessation in pregnancy. Expert Opin Drug Saf 2008;7:727-37
83. Crawford JT, Tolosa JE, Goldenberg RL. Smoking cessation in pregnancy: why, how, and what next. Clin Obstet Gynecol 2008;51:419-35 (Pubitemid 351655112)
84. Lumley J, Oliver S, Chamberlain C, Oakley L. Interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev 2004(4), doi: 10.1002/14651858.CD001055.pub2 [Art No.: CD001055]
85. McBride CM, Baucom DH, Peterson BL, Pollak KI, Palmer C, Westman E, et al. Prenatal and postpartum smoking abstinence a partner-assisted approach. Am J Prev Med 2004;27:232-8 (Pubitemid 39278323)
86. Rigotti NA, Park ER, Regan S, Chang Y, Perry K, Loudin B, et al. Efficacy of telephone counseling for pregnant smokers: a randomized controlled trial. Obstet Gynecol 2006;108:83-92 (Pubitemid 44336849)
87. Melvin CL, Dolan-Mullen P, Windsor RA, Whiteside Jr HP, Goldenberg RL. Recommended cessation counselling for pregnant women who smoke: a review of the evidence. Tob Control 2000;9(Suppl. 3):1180-4
88. Ruger JP, Emmons KM. Economic evaluations of smoking cessation and relapse prevention programs for pregnant women: a systematic review. Value Health 2008;11:180-90 (Pubitemid 351473613)
89. Hajek P, Stead LF, West R, Jarvis M, Lancaster T. Relapse prevention interventions for smoking cessation (Review). Cochrane Database Syst Rev 2009(1), doi: 10.1002/14651858.CD003999.pub3 [Art No.: CD003999]
90. Oncken C, Dornelas E, Greene J, Sankey H, Glasmann A, Feinn R, et al. Nicotine gum for pregnant smokers: a randomized controlled trial. Obstet Gynecol 2008;112:859-67
91. Kapur B, Hackman R, Selby P, Klein J, Koren G. Randomized, double- blind, placebo-controlled trial of nicotine replacement therapy in pregnancy. Curr Ther Res Clin Exp 2001;62:274-8 (Pubitemid 32411418)
92. Pollak KI, Oncken CA, Lipkus IM, Lyna P, Swamy GK, Pletsch PK, et al. Nicotine replacement and behavioral therapy for smoking cessation in pregnancy. Am J Prev Med 2007;33:297-305 (Pubitemid 47405143)
93. Dwyer JB, Broide RS, Leskie FM. Nicotine and brain development. Birth Defects Res C Embryo Today 2008;84:30-44 (Pubitemid 351499891)
94. Slotkin TA. If nicotine is a developmental neurotoxicant in animal studies, dare we recommend nicotine replacement therapy in pregnant women and adolescents? Neurotoxicol Teratol 2008;30:1-19
95. Gaither KH, Huber LR, Thompson ME, Huet-Hudson YM. Does the use of nicotine replacement therapy during pregnancy affect pregnancy outcomes? Matern Child Health J 2008;13:497-504
96. Morales-Suárez-Valera MM, Bille C, Christensen K, Olsen J. Smoking habits, nicotine use, and congenital malformations. Obstet Gynecol 2006;107:51-7
97. Pauley JR, Slotkin TA. Maternal tobacco smoking, nicotine replacement and neuro-behavioural development. Acta Pediatr 2008;97:1331-7
98. Coleman T. Recommendations for the use of pharmacological smoking cessation strategies in pregnant women. CNS Drugs 2007;21:983-93 (Pubitemid 350136782)
99. Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005;192:932-6 (Pubitemid 40311292)
100. Chan B, Einarson A, Koren G. Effectiveness of bupropion for smoking cessation during pregnancy. J Addict Dis 2005;24(2):19-23 (Pubitemid 40604648)
101. Luty J, Nikolaou V, Bearn J. Is opiate detoxification unsafe in pregnancy? J Subst Abuse Treat 2003;24:363-7 (Pubitemid 36809290)
102. Kashiwagi M, Arlettaz R, Lauper U, Zimmermann R, Hebisch G. Methadone maintenance program in a Swiss perinatal center: (I): management and outcome of 89 pregnancies. Acta Obstet Gynecol Scand 2005;84:140-4 (Pubitemid 40278801)
103. Dashe JS, Jackson GL, Olscher DA, Zane EH, Wenderl Jr GD. Opioid detoxification in pregnancy. Obstet Gynecol 1998;92:854-8 (Pubitemid 28487688)
104. Maas U, Katner E, Weingart-Jesse B, Schafer A, Obladen M. Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. J Perinat Med 1990;18:111-8 (Pubitemid 20162875)
105. Allen MH. Detoxification consideration in the medical management of substance abuse in pregnancy. Bull N Y Acad Med 1991;67:270-6
106. Blinick G, Inturrisi CE, Jerez E, Wallach RC. Methadone assays in pregnant women and progeny. Am J Obstet Gynecol 1975;121:617-21
107. Stern R. The pregnant addict. A study of 66 case histories, 1950-1959. Am J Obstet Gynecol 1966;94:253-7
108. Wilson GS, Desmond MM, Wait RB. Follow-up of methadone-treated and untreated narcotic-dependent women and their infants: health, developmental, and social implications. J Pediatr 1981;98:716-22 (Pubitemid 11070321)
109. Jones HE, O'Grady KE, Malfi D, Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict 2008;17: 372-86
110. Hagopian GS, Wolfe HM, Sokol RJ, Ager JW, Wardell JN, Cepeda EE. Neonatal outcome following methadone exposure in utero. J Matern Fetal Med 1996;5: 348-54
111. Kandall SR, Albin S, Lowinson J, Berle B, Eidelman AI, Gartner LM. Differential effects of maternal heroin and methadone use on birthweight. Pediatrics 1976;58:681-5
112. Hulse GK, Milne E, English DR, Holman CDJ. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 1997;92: 1571-9 (Pubitemid 27499568)
113. Zelson C, Lee SJ, Casalino M. Neonatal narcotic addiction. Comparative effects of maternal intake of heroin and methadone. N Eng J Med 1973;289(23):1216-20
114. Rahbar F. Observations on methadone withdrawal in 16 neonates. Clin Pediatr (Phila) 1975;14:369-71
115. Malpas TJ, Darlow BA, Lennox R, Horwood LJ. Maternal methadone dosage and neonatal withdrawal. Aust N Z J Obstet Gynecol 1995;35:175-7
116. Brown HL, Britton KA, Mahaffey D, Brizendine E, Hiett AK, Turnquest MA. Methadone maintenance in pregnancy: a reappraisal. Am J Obstet Gynecol 1998;179:459-63 (Pubitemid 28413384)
117. Arlettaz R, Kashiwagi M, Das-Kundu S, Fauchere JC, Lang A, Bucher HU. Methadone maintenance program in pregnancy in a Swiss perinatal center (II): neonatal outcome and social resources. Acta Obstet Gynecol Scand 2005;84: 145-50 (Pubitemid 40278802)
118. Hunt RW, Tzioumi D, Collins E, Jeffery HE. Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Hum Dev 2008;84:29-35
119. Vance JC, Chant DC, Tudehope DI, Gray PH, Hayes AJ. Infants born to narcotic dependent mothers: physical growth patterns in the first 12 months of life. J Paediatr Child Health 1997;33:504-8 (Pubitemid 28133730)
120. Lifshitz M, Gavrilov V, Galil A, Landau D. A four-year survey of neonatal narcotic withdrawal: evaluation and treatment. Isr Med Assoc J 2001;3:17-20 (Pubitemid 34176874)
121. McCarthy JJ, Leamon MH, Parr MS, Anania B. High-dosemethadonemaintenance in pregnancy:maternal andneonatal outcomes. Am J Obstet Gynecol 2005;193(3 Pt 1): 606-10
122. Jansson LM, Velez M, Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag 2009;5:47-55
123. Marcellus L. Care of the substance-exposed infants: the current state of practice in Canadian hospitals. J Perinat Neonatal Nurs 2002;16:51-68
124. Velez M, Jansson LM. The opioid dependent mother and newborn dyad: nonpharmacologic care. J Addict Med 2008;2(3):113-20
125. Osborn DA, Jeffery HE, Cole M. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2005(3), doi:10.1002/14651858. CD002059.pub2 [Art No.: CD002059]
126. Abrahams R, Kelly SA, Payne S, Thiessen PN, Mackintosh J, Janssen PA. Roomingin compared with standard care for newborns of mothers using methadone or heroin. Can Fam Physician 2007;53:1722-30 (Pubitemid 351194540)
127. Srivastava A, Kahan M. Buprenorphine: a potential new treatment option for opioid dependence. CMAJ 2006;174:1835-6 (Pubitemid 43974086)
128. Johnson R, Jones H, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003;70(2 Suppl.): S87-S101 (Pubitemid 36556063)
129. Lacroix I, Berrebi C, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase- Michel C. Buprenorphine in pregnant opioid dependent women: first results of a prospective study. Addiction 2004;99:209-14 (Pubitemid 38250755)
130. Lejeune C, Simmat Durand L, Gourarier L, Aubisson S, the Groupe d'Etudes Grossesse et Addictions (GEGA. Prospective multicenter observational study of 260 infants born to 259 opiate dependent mothers on methadone or high dose buprenorphine substitution. Drug Alcohol Depend 2006;82:250-7
131. Jones H, Johnson R, Jasinski DR, O'Grady KE, Chisholm CA, Choo RE, et al. Buprenorphine versus methadone in the treatment of pregnant opioid dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005;79:1-10 (Pubitemid 41557119)
132. Reisinger M. Use of buprenorphine during pregnancy. Res Clin Forums 1997;19: 43-5 (Pubitemid 27395510)
133. Schindler SD, Eder H, Ortner R, Rohrmeister K, Langer M, Fischer G. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction 2003;98:103-10 (Pubitemid 36044342)
134. National Opioid Use Guideline Group (NOUGG). Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. Available at:http://nationalpaincentre.mcmaster.ca/opioid. April 2010 [Accessed November 23, 2010]
135. College of Physicians and Surgeons of Ontario. Methadone for pain guidelines. Avialable at:http://www.cpso.on.ca/policies/guidelines/default.aspx? id=1986. Nov 2004 [Accessed January 21, 2011]
136. Hadi I, da Silva O, Natale R, Boyd D, Morley-Foster PK. Opioids in the parturient with chronic nonmalignant pain: a retrospective review. J Opioid Manag 2006;2: 31-4
137. Sharpe C, Kuschel C. Outcomes of infants born to mothers receiving methadone for pain management in pregnancy. Arch Dis Child Fetal Neonatal Ed 2004;89: F33-6 (Pubitemid 38125475)
138. Cassidy B, Cyna AM. Challenges that opioid-dependent women present to the obstetric anaesthetist. Anaesth Intensive Care 2004;32:494-501 (Pubitemid 39172454)
139. May JA, White HC, Leonard-White A, Warltier DC, Pagel PS. The patient recovering from alcohol or drug addiction: special issues for the anesthesiologist. Anesth Analg 2001;92:1601-8 (Pubitemid 32493191)
140. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 2002;100:213-7 (Pubitemid 35449233)
141. Rapp SE, Ready LB, Nessly ML. Acute pain management in patients with prior opioid consumption: a case-controlled retrospective review. Pain 1995;6: 195-201
142. Mehta V, Langford RM. Acute pain management for opioid dependent patients. Anaesthesia 2006;61:269-76 (Pubitemid 43337368)
143. Meyer M, Wagner K, Benvenuto A, Plante D, Howard D. Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy. Obstet Gynecol 2007;110:261-6 (Pubitemid 47356649)
144. Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. Treatment improvement protocol (TIP) 43. DHHS Publication No. (SMA) 05-4048. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2005. Available at:http://store.samhsa. gov/product/SMA09-4341. [Accessed January 5, 2011]
145. Perez-Reyes M, Wall ME. Presence of delta9-tetrahydrocannabinol in human milk. N Engl J Med 1982;307:819-20
146. Astley SJ, Little RE. Maternal marijuana use during lactation and infant development at one year. Neurotoxicol Teratol 1990;12:161-8 (Pubitemid 20177173)
147. Chasnoff IJ, Lewis DE, Squires L. Cocaine intoxication in a breast-fed infant. Pediatrics 1987;80:836-8 (Pubitemid 18020320)
148. Steiner E, Villen T, Hallberg M, Rane A. Amphetamine secretion in breast milk. Eur J Clin Pharmacol 1984;27:123-4 (Pubitemid 14045897)
149. Chaney NE, Franke J, Wadlington WB. Cocaine convulsions in a breast- feeding baby. J Pediatr 1988;112:134-5 (Pubitemid 18054287)
150. Hopkinson JM, Schanler RJ, Fraley JK, Garza C. Milk production by mothers of premature infants: influence of cigarette smoking. Pediatrics 1992;90:934-8
151. Robieux I, Koren G, Vanderbergh H, Schneiderman J. Morphine excretion in breast milk and resultant exposure of a nursing infant. J Toxicol Clin Toxicol 1990;28:365-70
152. Kreek MJ, Schecter A, Gutjahr CL, Bowen D, Field F, Queenan J, et al. Analyses of methadone and other drugs in maternal and neonatal body fluids: use in evaluation of symptoms in a neonate of mother maintained on methadone. Am J Drug Alcohol Abuse 1974;1:409-19
153. Pond SM, Kreek MJ, Tong TG, Raghunath J, Benowitz N. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther 1985;233:1-6 (Pubitemid 15083518)
154. Geraghty B, Graham EA, Logan B, Weiss EL. Methadone levels in breast milk. J Hum Lact 1997;13:227-30 (Pubitemid 127498676)
155. Johnson RE, Jones HE, Jasinki DR, Svikis DS, Haug NA, Jansson LM, et al. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 2001;63:97-103 (Pubitemid 32293533)
156. Marquet P, Chevrel J, Lavignasse P, Merle L, Lacatre G. Buprenorphine withdrawal syndrome in a newborn. Clin Pharmacol Ther 1997;62:569-71 (Pubitemid 28214935)
157. McCarthy JJ, Posey BL.Methadone levels in humanmilk. JHumLact 2000;16:115-20
158. Madadi P, Koren G. Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics 2008;9:1267-84
159. Madadi P, Ross CJ, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther 2009;85:31-5
160. Madadi P, Moretti M, Djokanovic N, Bozzo P, Nulman I, Ito S, et al. Guidelines for maternal codeine use during breastfeeding. Can Fam Physician 2009;55:1077-8
161. Woolf SH, Battista RN, Angerson GM, Logan AG, Eel W, Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care. CMAJ 2003;169:207-8.